Metrics as of 10/17/2026, 08:26 AM (Berlin time), refresh in progress.
Nanobiotix Stock
Nanobiotix S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Laurent Levy
- Employees
- 97
- Market cap
- $1.1 B
- IPO
- 11/12/2020
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on the development of innovative therapeutic solutions for cancer. The company's leading experimental drug is NBTXR3, which consists of a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Nanobiotix stock: price history
1D
-4.2%
1W
-10.1%
1M
-38.1%
6M
-37.0%
YTD
-7.9%
1Y
-19.8%
2Y
+336.5%
5Y
+66.1%
10Y
–
Next earnings date
Next earnings date
27/04/2027 (in 192 days)
Volatility around earnings
~32% weaker price swings than usual
Ask the agents about Nanobiotix
Analyst assessment of Nanobiotix
PRICE TARGET LOW
US$30.00
CONSENSUS
US$38.00
MEDIAN
US$38.00
PRICE TARGET HIGH
US$46.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 04/06/2026
Nanobiotix stock metrics
P/E
-17.38
P/B
-28
EV/EBITDA
-29.66
RETURN ON EQUITY
104.1%
NET MARGIN
-626.0%
DEBT/EQUITY
-3.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.9%
FLOAT SHARES
41,613,976
AVG. DAILY VOLUME (30D)
142,778
Institutional holders
Comparable stocks
Frequently asked questions about Nanobiotix stock
What does Nanobiotix do?
Nanobiotix S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Laurent Levy, the company employs around 97 people.
The IPO was on 11/12/2020; the stock trades on NASDAQ under the ticker NBTX.
What do analysts say about Nanobiotix stock?
4 analysts rate the stock, the consensus is Buy (as of 04/06/2026).
The average price target is US$38.00, ranging from US$30.00 to US$46.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does Nanobiotix report next?
The next earnings date is 27/04/2027.
Around past earnings, price swings were roughly -32% stronger than usual.
Does Nanobiotix pay a dividend?
No, Nanobiotix currently does not pay a dividend.
Which stocks are comparable to Nanobiotix?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Nanobiotix stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nanobiotix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.